News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zealand Pharma Announces New Results on Lixisenatide (Lyxumia(R)1) for Type 2 Diabetes Presented by Sanofi (France) (SASY.PA) at the 21st World Diabetes Congress



12/5/2011 9:49:37 AM

COPENHAGEN, Denmark, Dec. 5, 2011 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL), a Danish biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs, announces that new results on lixisenatide (Lyxumia(R)) will be presented by the company's partner Sanofi at the International Diabetes Federation's 21st World Diabetes Congress, 5 - 8 December 2011 in Dubai, United Arab Emirates. Lixisenatide is an investigational new GLP-1 agonist for once-daily dosing, discovered by Zealand Pharma and developed by Sanofi for the treatment of Type 2 diabetes.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES